Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 21, 2012 - Issue 10
Submit an article Journal homepage
409
Views
2
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

The therapeutic potential of PCSK9 inhibition in primary dyslipidemia, the example from SAR236553/REGN727

McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase Subtilisin/Kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012. [Epub ahead of print].

Amar M SalamHamad Medical Corp., P.O. Box 3050, Doha, Qatar+974 447 45408; +974 447 45616; [email protected]
, MBBS FRCP (London) FACC
Pages 1585-1588 | Published online: 19 Jul 2012

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.